Belite Bio announces its submission to the Pharmaceuticals and Medical Devices Agency, PMDA, to initiate a clinical trial of Tinlarebant in adolescent STGD1 in Japan, DRAGON II. The DRAGON II trial is a combination of Phase 1b open-label study to evaluate the pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese adolescent STGD1 subjects and a Phase 2/3, global, multicenter, double-masked, placebo-controlled, randomized study designed to evaluate the efficacy, safety and tolerability of Tinlarebant in adolescent STGD1 subjects. Approximately 60 subjects, aged 12 to 20 years old, including approximately 10 Japanese subjects, are targeted for enrollment in the Phase 2/3 portion of the trial with a 1:1 randomization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio reports Q4 EPS (27c), consensus (30c)
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
- Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
- Belite Bio participates in a conference call with Benchmark
